In Cambridge, Massachusetts, on June 22, 2026, Insilico Medicine (3696.HK) announced their collaboration with SK Biopharmaceuticals, a leading biotech company from Korea. Insilico is a clinical-stage company utilizing generative artificial intelligence (AI) for drug discovery. This partnership aims to revolutionize the field with innovative drugs.